首页 | 本学科首页   官方微博 | 高级检索  
检索        

蓝芩口服液联合头孢克肟治疗小儿急性咽炎的临床研究
引用本文:付晓梅,王青青,张宏,张国伟,吕民英,齐莎莎,王莎,孟凡威,况琦.蓝芩口服液联合头孢克肟治疗小儿急性咽炎的临床研究[J].现代药物与临床,2021,36(1):161-164.
作者姓名:付晓梅  王青青  张宏  张国伟  吕民英  齐莎莎  王莎  孟凡威  况琦
作者单位:河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001;河南大学第一附属医院 儿科,河南 开封 475001
基金项目:国家自然科学基金资助项目(81774304);陕西省中医药管理局科研课题(2019-GJ-QT002)
摘    要:目的 系统评价百令胶囊辅助治疗糖尿病肾病的有效性和安全性。方法 计算机检索PubMed、中国学术期刊全文数据库(CNKI)、维普中文期刊全文数据库(VIP)、中国生物医学文献数据库(CBM)和万方数据库中有关百令胶囊单独或联合其他药物治疗糖尿病肾病的临床随机对照试验(RCT),检索时间从各数据库建库至2020年1月,按照纳入与排除标准将筛选出的文献进行信息提取与质量评价,采用RevMan5.3软件进行Meta分析。结果 共纳入12篇RCTs,包括1 011例患者。Meta分析结果显示:与对照组相比,百令胶囊能提高糖尿病肾病患者临床疗效[OR=5.04,95% CI=(3.16,8.03),P<0.000 01],并降低尿白蛋白排泄率[SMD=-1.95,95% CI=(-2.74,-1.17),P<0.000 01]、血肌酐[SMD=-2.14,95% CI=(-3.57,-0.71),P=0.003]、24 h尿蛋白定量[SMD=-1.56,95% CI=(-2.45,-0.76),P=0.000 1]及空腹血糖[SMD=-0.52,95% CI=(-0.59,-0.47),P<0.000 01];纳入文献均描述未发生不良反应。结论 百令胶囊对糖尿病肾病有一定的疗效且安全性较好,值得临床借鉴;但由于本研究存在一定不足之处,故需质量更高、样本量较大的临床研究进一步证实。

关 键 词:蓝芩口服液  头孢克肟颗粒  急性咽炎  肿瘤坏死因子-α  C反应蛋白  不良反应
收稿时间:2020/6/21 0:00:00

Clinical study on Lanqin Oral Liquid combined with cefixime in treatment of acute pharyngitis in children
GAO Yan,SONG Zongliang,DUAN Yuhong,ZHANG Xiaoke.Clinical study on Lanqin Oral Liquid combined with cefixime in treatment of acute pharyngitis in children[J].Drugs & Clinic,2021,36(1):161-164.
Authors:GAO Yan  SONG Zongliang  DUAN Yuhong  ZHANG Xiaoke
Institution:Shaanxi University of Chinese Medicine, Xianyang 712046, China;Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
Abstract:Objective To systematically evaluate the efficacy and safety of Bailing Capsule for treating diabetic kidney disease (DKD). Methods Randomized controlled trials of Bailing Capsule in the treatment of DKD was collected by searching PubMed, CNKI, VIP, CBM and Wanfang databases by computer from inception to January 2020. Extract the information and evaluate the quality of the included literature. RevMan 5.3 software was used for Meta-analysis. Results A total of 12 studies involving 1 011 patients were included into the study. The results of meta-analysis showed that Bailing Capsule in the treatment of DKD can improve total effective rateOR=5.04, 95%CI=(3.16, 8.03), P<0.000 01] and decrease urinary albumin excretion rateSMD=-1.95, 95%CI=(-2.74, -1.17), P<0.000 01], serum creatinineSMD=-2.14, 95%CI=(-3.57, -0.71), P=0.003], 24-hour urine proteinSMD=-1.56, 95%CI=(-2.45, -0.76), P=0.000 1] and fasting blood glucoseSMD=-0.52, 95%CI=(-0.59, -0.47), P<0.000 01]. No adverse reactions were reported in all the included literatures. Conclusion Bailing Capsule have certain effect to treat DKD and the safety is good, which is worthy of being learned in clinic. However, there are some deficiencies in this study, so more highquality and large sample clinical studies are still needed to further confirm.
Keywords:Bailing Capsule  diabetic kidney disease  clinical efficacy  Meta-analysis
本文献已被 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号